The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Differentiate between prognostic and predictive factors in early-stage breast cancer. Identify prognostic factors used to determine the risk of recurrence and death for a patient with early-stage breast cancer. Identify predictive factors used to determine the optimal therapy for a patient with early-stage breast cancer. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Breast cancer is the most common malignancy among American women. Due to increased screening, the majority of patients present with early-stage breast cancer. The Oxford Overview Analysis demonstrates that adjuvant hormonal therapy and polychemotherapy reduce the risk of recurrence and death from breast cancer. Adjuvant systemic therapy, however, has associated risks and it would be useful to be able to optimally select patients most likely to benefit. The purpose of adjuvant systemic therapy is to eradicate distant micrometastatic deposits. It is essential therefore to be able to estimate an individual patient's risk of harboring clinically silent micrometastatic disease using established prognostic factors. It is also beneficial to be able to select the optimal adjuvant therapy for an individual patient based on established predictive factors. It is standard practice to administer systemic therapy to all patients with lymph node-positive disease. However, there are clearly differences among node-positive women that may warrant a more aggressive therapeutic approach. Furthermore, there are many node-negative women who would also benefit from adjuvant systemic therapy. Prognostic factors therefore must be differentiated from predictive factors. A prognostic factor is any measurement available at the time of surgery that correlates with disease-free or overall survival in the absence of systemic adjuvant therapy and, as a result, is able to correlate with the natural history of the disease. In contrast, a predictive factor is any measurement associated with response to a given therapy. Some factors, such as hormone receptors and HER2/neu overexpression, are both prognostic and predictive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma
Morton, D. L. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420040034005 · Cited by 4,371
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Bloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Carter, C. L., Allen, C., & Henson, D. E. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h · Cited by 2,288
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Cited by
Dunnwald, L. K., Rossing, M. A., & Li, C. I. (2007) · Breast Cancer Research · doi:10.1186/bcr1639 · Cited by 785
Youlden, D. R., Cramb, S. M., Dunn, N. A. M., Muller, J. M., Pyke, C. M., & Baade, P. D. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.02.007 · Cited by 709
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer
Juríková, M., Danihel, Ľ., Polák, Š., & Varga, I. (2016) · Acta Histochemica · doi:10.1016/j.acthis.2016.05.002 · Cited by 608
Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer
Wu, C., Yin, P., Hung, W., Li, A. F., Li, S., Chi, C., Wei, Y., & Lee, H. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20213 · Cited by 381
Metadata
- Authors
- Cianfrocca, M., & Goldstein, L. J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-01
- Volume
- 9
- Issue
- 6
- Pages
- 606-616
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2159489835
- Cited by
- 637
- References
- 49
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic and Predictive Factors in Early-Stage Breast Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.9-6-606
- The paper
- Cianfrocca, M., & Goldstein, L. J. (2004). Prognostic and Predictive Factors in Early-Stage Breast Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.9-6-606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.